|
|
Anavex presents data on potential dual utility of ANAVEX 2-73 in both amyloid and tau pathology
Sources News Release
http://www.sources.com/Releases/NR1381.htm
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 25/07/2011
Year Published: 2011
Resource Type: Article
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of the first of two poster presentations at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “The novel aminotetrahydrofuran deriva
Abstract: Hoboken, NJ – July 25, 2011 -- Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide a summary of the first of two poster presentations at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “The novel aminotetrahydrofuran derivative ANAVEX 2-73 attenuated GSK-3beta and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model in mice.”
Researchers injected oligomeric amyloid 25-35 fragments into the brain of mice in order to mi...
To read the full release go to http://www.sources.com/Releases/NR1381.htm
Topics
|
AlterLinks
c/o Sources
© 2023.
|
|
|
|
